Literature DB >> 25846421

Lymph node status in inflammatory breast cancer.

Julie S Wecsler1, Welela Tereffe, Rose C Pedersen, Michelle R Sieffert, Wendy J Mack, Haiyan Cui, Christy A Russell, Ryan R Woods, Rebecca K Viscusi, Stephen F Sener, Julie E Lang.   

Abstract

Positive lymph node status in breast cancer is known to be an adverse prognostic factor, but the effect of lymph node (LN) status in inflammatory breast cancer (IBC) has not been evaluated. This study was designed to investigate the association between lymph node status and overall survival (OS) in individuals with IBC. Using the Surveillance, Epidemiology, and End Results (SEER) 18 registry, we collected data on 761 patients diagnosed with non-metastatic IBC from 2004 to 2008. Survival analysis was performed using the Kaplan-Meier method. Cox proportional hazard regression was performed to evaluate univariate and multivariate associations between estrogen and progesterone receptor (ER/PR) status, treatment, and OS. Positive nodal status was associated with a significant decrease in OS (p < 0.001). Five-year survival for LN-positive and LN-negative patients was 49 and 66 %, respectively. In node-positive patients, ER or PR positivity was associated with improved OS, (p = 0.025, p = 0.007). In node-positive patients, the combination of surgery and radiation therapy improved OS when compared with surgery alone (p = 0.002). Nearly 80 % of the patients in this study had nodal metastasis. Positive nodal status was found to be an adverse prognostic factor. ER/PR positivity and treatment with surgery and radiation in node-positive patients was found to improve outcomes. Further studies are required to characterize the biology of IBC and guide the optimal treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25846421      PMCID: PMC7032612          DOI: 10.1007/s10549-015-3367-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  25 in total

Review 1.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Authors:  M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

Review 2.  Inflammatory breast cancer: what progress have we made?

Authors:  Shaheenah Dawood; Massimo Cristofanilli
Journal:  Oncology (Williston Park)       Date:  2011-03       Impact factor: 2.990

3.  Identifying factors that impact survival among women with inflammatory breast cancer.

Authors:  S Dawood; N T Ueno; V Valero; W A Woodward; T A Buchholz; G N Hortobagyi; A M Gonzalez-Angulo; M Cristofanilli
Journal:  Ann Oncol       Date:  2011-07-15       Impact factor: 32.976

4.  Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

Authors:  B Fisher; A Brown; E Mamounas; S Wieand; A Robidoux; R G Margolese; A B Cruz; E R Fisher; D L Wickerham; N Wolmark; A DeCillis; J L Hoehn; A W Lees; N V Dimitrov
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

5.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

Authors:  H M Kuerer; L A Newman; T L Smith; F C Ames; K K Hunt; K Dhingra; R L Theriault; G Singh; S M Binkley; N Sneige; T A Buchholz; M I Ross; M D McNeese; A U Buzdar; G N Hortobagyi; S E Singletary
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

6.  Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer.

Authors:  Vered Stearns; C Alexander Ewing; Rebecca Slack; Marie F Penannen; Daniel F Hayes; Theodore N Tsangaris
Journal:  Ann Surg Oncol       Date:  2002-04       Impact factor: 5.344

7.  Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study.

Authors:  Shaheenah Dawood; Naoto T Ueno; Vicente Valero; Wendy A Woodward; Thomas A Buchholz; Gabriel N Hortobagyi; Ana Maria Gonzalez-Angulo; Massimo Cristofanilli
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

8.  Trends for inflammatory breast cancer: is survival improving?

Authors:  Ana M Gonzalez-Angulo; Bryan T Hennessy; Kristine Broglio; Funda Meric-Bernstam; Massimo Cristofanilli; Sharon H Giordano; Thomas A Buchholz; Aysegul Sahin; S Eva Singletary; Aman U Buzdar; Gabriel N Hortobágyi
Journal:  Oncologist       Date:  2007-08

9.  Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience.

Authors:  Massimo Cristofanilli; Ana Maria Gonzalez-Angulo; Aman U Buzdar; Shu-Wan Kau; Debbie K Frye; Gabriel N Hortobagyi
Journal:  Clin Breast Cancer       Date:  2004-02       Impact factor: 3.225

10.  Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.

Authors:  Jason A Zell; Walter Y Tsang; Thomas H Taylor; Rita S Mehta; Hoda Anton-Culver
Journal:  Breast Cancer Res       Date:  2009-02-19       Impact factor: 6.466

View more
  7 in total

1.  RhoC GTPase Is a Potent Regulator of Glutamine Metabolism and N-Acetylaspartate Production in Inflammatory Breast Cancer Cells.

Authors:  Michelle L Wynn; Joel A Yates; Charles R Evans; Lauren D Van Wassenhove; Zhi Fen Wu; Sydney Bridges; Liwei Bao; Chelsea Fournier; Sepideh Ashrafzadeh; Matthew J Merrins; Leslie S Satin; Santiago Schnell; Charles F Burant; Sofia D Merajver
Journal:  J Biol Chem       Date:  2016-04-25       Impact factor: 5.157

2.  Nomograms for Estimating Cause-Specific Death Rates of Patients With Inflammatory Breast Cancer: A Competing-Risks Analysis.

Authors:  Fengshuo Xu; Jin Yang; Didi Han; Qiao Huang; Chengzhuo Li; Shuai Zheng; Hui Wang; Jun Lyu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

3.  Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics.

Authors:  Tithi Biswas; Charulata Jindal; Timothy L Fitzgerald; Jimmy T Efird
Journal:  Int J Environ Res Public Health       Date:  2019-01-04       Impact factor: 3.390

4.  Nomogram for predicting cancer specific survival in inflammatory breast carcinoma: a SEER population-based study.

Authors:  Haige Zhang; Guifen Ma; Shisuo Du; Jing Sun; Qian Zhang; Baoying Yuan; Xiaoyong Luo
Journal:  PeerJ       Date:  2019-09-16       Impact factor: 2.984

5.  Trends in Sentinel Lymph Node Biopsies in Patients With Inflammatory Breast Cancer in the US.

Authors:  Alan Sosa; Xiudong Lei; Wendy A Woodward; Mariana Chavez Mac Gregor; Anthony Lucci; Sharon H Giordano; Kevin T Nead
Journal:  JAMA Netw Open       Date:  2022-02-01

6.  The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study.

Authors:  Mahvish Muzaffar; Helen M Johnson; Nasreen A Vohra; Darla Liles; Jan H Wong
Journal:  Int J Breast Cancer       Date:  2018-06-03

Review 7.  Pathological and molecular characteristics of inflammatory breast cancer.

Authors:  Maurizio Di Bonito; Monica Cantile; Gerardo Botti
Journal:  Transl Cancer Res       Date:  2019-10       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.